Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reaferon-ES-Lipint
- Development stage
- Unknown
- Lead developer
- Vector-Medica
- Modality
- Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
Reaferon-ES-Lipint is an orally administered, liposomal formulation of recombinant human interferon alpha-2b developed and manufactured by the Russian company Vector-Medica. The drug consists of interferon alpha-2b produced in an *Escherichia coli* expression system (denoted by the 'ES' suffix), encapsulated within liposomes to protect the protein from proteolytic degradation in the gastrointestinal tract and facilitate systemic absorption. As a type I interferon, it functions by binding to the interferon alpha/beta receptor (IFNAR), which activates the JAK-STAT signaling pathway. This leads to the induction of an antiviral state in host cells and the modulation of both innate and adaptive immune responses. It is approved in Russia for the treatment and prophylaxis of a wide range of viral and bacterial infections, including influenza, acute respiratory viral infections (ORVI), tick-borne encephalitis, chronic hepatitis B, and chlamydial infections.
- Brand names
- Реаферон-ЕС-ЛипинтReaferon-ES-Lipint
- Other names
- Реаферон-ЛипинтReaferon-Lipintliposomal recombinant interferon-alpha 2b
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on Reaferon-ES-Lipint.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reaferon-ES-Lipint.